Skip to main content
. 2018 Nov 1;9:4572. doi: 10.1038/s41467-018-06690-4

Fig. 3.

Fig. 3

MAPK pathway activation in GCLJ. Immunohistochemical (IHC) staining for phospho-ERK1/2 shows strong positive staining in mononucleated cells in GCLJ lesions. Representative images of phospho-ERK1/2 staining in TRPV4 p.M713V (a), KRAS p.G12D (b), and FGFR1 p.C831R (c) mutant and in WT (d) GCLJ cases. e Immunoblot showing sustained phospho-ERK1/2 (pERK1/2) activation in TRPV4 M713I HEK293 mutant cells compared to WT. A representative experiment of three independent assays is provided. Scale bar represents 200 μm